Keyphrases
Hepatocellular Carcinoma
94%
Taiwan
24%
Hepatocellular Carcinoma Patients
24%
Transarterial Chemoembolization
18%
Chronic Hepatitis C
14%
Hepatitis C
13%
Albumin-bilirubin Grade
13%
Confidence Interval
13%
Radiofrequency Ablation
13%
Cirrhosis
13%
Overall Survival
13%
Hepatitis C Virus
13%
Hazard Ratio
13%
Surgical Resection
11%
Hepatitis B Virus
11%
Alpha-fetoprotein
10%
Direct-acting Antivirals
9%
Prognostic Factors
9%
Hepatitis B Surface Antigen (HBsAg)
9%
Barcelona Clinic Liver Cancer
8%
Chronic Hepatitis B
8%
Sustained Virological Response
8%
Advanced Hepatocellular Carcinoma
8%
Multivariate Analysis
7%
Risk Factors
7%
MELD Score
7%
Cirrhotic Patients
7%
Immune Checkpoint Inhibitors
7%
Propensity Score Analysis
7%
Unresectable Hepatocellular Carcinoma
7%
Liver Cirrhosis
7%
Performance Status
6%
Resection
6%
Liver Reserve Function
6%
Locoregional Therapy
6%
Tumor Recurrence
5%
Hepatitis D Virus
5%
Hepatitis B e Antigen (HBeAg)
5%
Tumor Size
5%
Chronic Hepatitis B Patients
5%
Cox Proportional Hazards Model
5%
Portal Hypertension
5%
Ascites
5%
Prognostic Impact
5%
Hepatitis B
5%
Milan Criteria
5%
Liver
5%
Antiretroviral Therapy
5%
Prognostic Model
5%
Microvascular Invasion
5%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Transcatheter Arterial Chemoembolization
19%
Neoplasm
17%
Liver Cirrhosis
17%
Surgery
15%
Bilirubin
13%
Overall Survival
13%
Hepatitis B Virus
13%
Liver Cancer
11%
Radiofrequency Ablation
11%
Chronic Hepatitis C
11%
Hazard Ratio
10%
Hepatitis C Virus
8%
Chronic Hepatitis B
8%
Cancer Staging
8%
Platelet
8%
Antivirus Agent
7%
Hepatitis B
7%
Proportional Hazards Model
6%
Antiviral Therapy
6%
Hepatitis C
6%
Milan Criteria
6%
Recurrent Disease
5%
Immune Checkpoint Inhibitor
5%
Malignant Neoplasm
5%
Multivariate Analysis
5%
Fibrosis
5%
Fetoprotein
5%
Immunotherapy
5%
Model for End-Stage Liver Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
85%
Hepatitis B Virus
19%
Neoplasm
16%
Liver Cirrhosis
15%
Overall Survival
15%
Antivirus Agent
13%
Chronic Hepatitis C
12%
Bilirubin
12%
Chronic Hepatitis B
11%
Hepatitis C Virus
9%
Mouse
8%
Hepatitis C
8%
Hepatitis B
8%
Recurrent Disease
7%
Immune Checkpoint Inhibitor
7%
Infection
7%
Disease
7%
Immunotherapy
6%
Fibrosis
6%
Liver Fibrosis
6%
Malignant Neoplasm
6%
Hepatitis B Antigen
6%
Hepatitis B(e) Antigen
6%
End Stage Liver Disease
6%
Liver Injury
5%
Adverse Event
5%
Sorafenib
5%
Nonalcoholic Fatty Liver
5%
Tumor Recurrence
5%
Fetoprotein
5%
Cancer Staging
5%
Sofosbuvir
5%
Progression Free Survival
5%